Literature DB >> 34355176

Recent advances in the development of covalent inhibitors.

Hyunsoo Kim1, Yoon Soo Hwang1, Mingi Kim1, Seung Bum Park1,2,3.   

Abstract

The use of covalent inhibitors in the field of drug discovery has attracted considerable attention in the 2000s. As a result, more than 50 covalent drugs are currently on the market, and numerous covalent drug candidates are now under development. Therefore, interest in covalent drugs is expected to continue in the future. The purpose of this focused review is to provide an understanding of the development of covalent inhibitors by describing their inherent characteristics, possibilities, and limitations based on their mechanistic differences from noncovalent inhibitors. We also introduce the latest covalent warheads that can be applied to the development of potential covalent inhibitors. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2021        PMID: 34355176      PMCID: PMC8292994          DOI: 10.1039/d1md00068c

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  43 in total

1.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.

Authors:  Cai-Hong Yun; Kristen E Mengwasser; Angela V Toms; Michele S Woo; Heidi Greulich; Kwok-Kin Wong; Matthew Meyerson; Michael J Eck
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-28       Impact factor: 11.205

Review 2.  The resurgence of covalent drugs.

Authors:  Juswinder Singh; Russell C Petter; Thomas A Baillie; Adrian Whitty
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

Review 3.  Covalent inhibitors design and discovery.

Authors:  Stephane De Cesco; Jerry Kurian; Caroline Dufresne; Anthony K Mittermaier; Nicolas Moitessier
Journal:  Eur J Med Chem       Date:  2017-06-10       Impact factor: 6.514

4.  SuFEx-enabled, agnostic discovery of covalent inhibitors of human neutrophil elastase.

Authors:  Qinheng Zheng; Jordan L Woehl; Seiya Kitamura; Diogo Santos-Martins; Christopher J Smedley; Gencheng Li; Stefano Forli; John E Moses; Dennis W Wolan; K Barry Sharpless
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-04       Impact factor: 11.205

5.  Translating slow-binding inhibition kinetics into cellular and in vivo effects.

Authors:  Grant K Walkup; Zhiping You; Philip L Ross; Eleanor K H Allen; Fereidoon Daryaee; Michael R Hale; John O'Donnell; David E Ehmann; Virna J A Schuck; Ed T Buurman; Allison L Choy; Laurel Hajec; Kerry Murphy-Benenato; Valerie Marone; Sara A Patey; Lena A Grosser; Michele Johnstone; Stephen G Walker; Peter J Tonge; Stewart L Fisher
Journal:  Nat Chem Biol       Date:  2015-04-20       Impact factor: 15.040

Review 6.  Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery.

Authors:  Kenneth K Hallenbeck; David M Turner; Adam R Renslo; Michelle R Arkin
Journal:  Curr Top Med Chem       Date:  2017       Impact factor: 3.295

7.  2-Sulfonylpyridines as Tunable, Cysteine-Reactive Electrophiles.

Authors:  Claudio Zambaldo; Ekaterina V Vinogradova; Xiaotian Qi; Jonathan Iaconelli; Radu M Suciu; Minseob Koh; Kristine Senkane; Stormi R Chadwick; Brittany B Sanchez; Jason S Chen; Arnab K Chatterjee; Peng Liu; Peter G Schultz; Benjamin F Cravatt; Michael J Bollong
Journal:  J Am Chem Soc       Date:  2020-04-29       Impact factor: 15.419

8.  Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors.

Authors:  Kirsten McAulay; Emily A Hoyt; Morgan Thomas; Marianne Schimpl; Michael S Bodnarchuk; Hilary J Lewis; Derek Barratt; Deepa Bhavsar; David M Robinson; Michael J Deery; Derek J Ogg; Gonçalo J L Bernardes; Richard A Ward; Michael J Waring; Jason G Kettle
Journal:  J Am Chem Soc       Date:  2020-06-02       Impact factor: 15.419

Review 9.  Covalent inhibitors: a rational approach to drug discovery.

Authors:  Fandi Sutanto; Markella Konstantinidou; Alexander Dömling
Journal:  RSC Med Chem       Date:  2020-07-02

10.  Covalent inhibition of NSD1 histone methyltransferase.

Authors:  Huang Huang; Christina A Howard; Sergei Zari; Hyo Je Cho; Shirish Shukla; Hao Li; Juliano Ndoj; Paula González-Alonso; Caroline Nikolaidis; Joshua Abbott; David S Rogawski; Mykhaylo A Potopnyk; Katarzyna Kempinska; Hongzhi Miao; Trupta Purohit; Andrew Henderson; Anna Mapp; Maria Luisa Sulis; Adolfo Ferrando; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Nat Chem Biol       Date:  2020-08-31       Impact factor: 15.040

View more
  3 in total

Review 1.  Covalent cannabinoid receptor ligands - structural insight and selectivity challenges.

Authors:  Ian Liddle; Michelle Glass; Joel D A Tyndall; Andrea J Vernall
Journal:  RSC Med Chem       Date:  2022-04-04

2.  CovPDB: a high-resolution coverage of the covalent protein-ligand interactome.

Authors:  Mingjie Gao; Aurélien F A Moumbock; Ammar Qaseem; Qianqing Xu; Stefan Günther
Journal:  Nucleic Acids Res       Date:  2022-01-07       Impact factor: 16.971

3.  Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization.

Authors:  Veronica Di Sarno; Gianluigi Lauro; Simona Musella; Tania Ciaglia; Vincenzo Vestuto; Marina Sala; Maria Carmina Scala; Gerardina Smaldone; Francesca Di Matteo; Sara Novi; Mario Felice Tecce; Ornella Moltedo; Giuseppe Bifulco; Pietro Campiglia; Isabel M Gomez-Monterrey; Robert Snoeck; Graciela Andrei; Carmine Ostacolo; Alessia Bertamino
Journal:  Eur J Med Chem       Date:  2021-09-22       Impact factor: 6.514

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.